224 related articles for article (PubMed ID: 32461187)
21. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
[TBL] [Abstract][Full Text] [Related]
22. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
Iyer PC; Dadu R; Gule-Monroe M; Busaidy NL; Ferrarotto R; Habra MA; Zafereo M; Williams MD; Gunn GB; Grosu H; Skinner HD; Sturgis EM; Gross N; Cabanillas ME
J Immunother Cancer; 2018 Jul; 6(1):68. PubMed ID: 29996921
[TBL] [Abstract][Full Text] [Related]
23. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
[TBL] [Abstract][Full Text] [Related]
24. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
25. Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma.
Boudin L; Morvan JB; Thariat J; Métivier D; Marcy PY; Delarbre D
Curr Oncol; 2022 Oct; 29(10):7718-7731. PubMed ID: 36290887
[TBL] [Abstract][Full Text] [Related]
26. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment.
Iesato A; Li S; Sadow PM; Abbasian M; Nazarian A; Lawler J; Nucera C
Thyroid; 2023 Jul; 33(7):835-848. PubMed ID: 37171127
[No Abstract] [Full Text] [Related]
27. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy and Safety of Lenvatinib for Unresectable Anaplastic Thyroid Cancer].
Yamazaki H; Shimizu S; Iwasaki H; Yoshida T; Suganuma N; Yamanaka T; Kojima I; Masudo K; Toda S; Nakayama H; Masuda M
Gan To Kagaku Ryoho; 2017 Aug; 44(8):695-697. PubMed ID: 28860443
[TBL] [Abstract][Full Text] [Related]
29. KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma.
Wang Z; Qiu X; Zhang H; Li W
J Biochem Mol Toxicol; 2020 May; 34(5):e22469. PubMed ID: 32173973
[TBL] [Abstract][Full Text] [Related]
30. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
Voigt W; Kegel T; Weiss M; Mueller T; Simon H; Schmoll HJ
J Cancer Res Clin Oncol; 2005 Sep; 131(9):585-90. PubMed ID: 16021466
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
32. Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib.
Fukuda N; Toda K; Fujiwara YU; Wang X; Ohmoto A; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Mitani H; Takahashi S
In Vivo; 2020; 34(5):2859-2864. PubMed ID: 32871825
[TBL] [Abstract][Full Text] [Related]
33. Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer.
Banchi M; Orlandi P; Gentile D; Alì G; Fini E; Fontanini G; Francia G; Bocci G
Am J Cancer Res; 2020; 10(7):2120-2127. PubMed ID: 32775005
[TBL] [Abstract][Full Text] [Related]
34. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).
Higashiyama T; Sugino K; Hara H; Ito KI; Nakashima N; Onoda N; Tori M; Katoh H; Kiyota N; Ota I; Suganuma N; Hibi Y; Nemoto T; Takahashi S; Yane K; Ioji T; Kojima S; Kaneda H; Sugitani I; Tahara M
Eur J Cancer; 2022 Sep; 173():210-218. PubMed ID: 35932627
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer.
Lin SF; Yeh CN; Huang YT; Chou TC; Wong RJ
Cancer Sci; 2021 Feb; 112(2):803-814. PubMed ID: 33306266
[TBL] [Abstract][Full Text] [Related]
37. PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration.
Che HY; Guo HY; Si XW; You QY; Lou WY
Tumour Biol; 2014 Sep; 35(9):8659-64. PubMed ID: 24867098
[TBL] [Abstract][Full Text] [Related]
38. Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.
Di Desidero T; Antonelli A; Orlandi P; Ferrari SM; Fioravanti A; Alì G; Fontanini G; Basolo F; Francia G; Bocci G
Cancer Lett; 2017 Dec; 411():35-43. PubMed ID: 28964784
[TBL] [Abstract][Full Text] [Related]
39. Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe.
Barbaro D; Lapi P; Viacava P; Torregrossa L
BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33370973
[TBL] [Abstract][Full Text] [Related]
40. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
Wirth LJ; Brose MS; Sherman EJ; Licitra L; Schlumberger M; Sherman SI; Bible KC; Robinson B; Rodien P; Godbert Y; De La Fouchardiere C; Newbold K; Nutting C; Misir S; Xie R; Almonte A; Ye W; Cabanillas ME
J Clin Oncol; 2021 Jul; 39(21):2359-2366. PubMed ID: 33961488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]